These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31676346)

  • 1. Activating alternative chloride channels to treat CF: Friends or Foes?: Report on the Meeting of the Basic Science Working Group in Dubrovnik, Croatia.
    Amaral MD; Beekman JM
    J Cyst Fibros; 2020 Jan; 19(1):11-15. PubMed ID: 31676346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cystic fibrosis: Beyond the airways. Report on the meeting of the basic science working group in Loutraki, Greece.
    Amaral MD; Boj SF; Shaw J; Leipziger J; Beekman JM
    J Cyst Fibros; 2018 Jul; 17(4):441-443. PubMed ID: 29866530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cystic fibrosis research topics featured at the 14th ECFS Basic Science Conference: Chairman's summary.
    Mall MA; Hwang TC; Braakman I
    J Cyst Fibros; 2018 Mar; 17(2S):S1-S4. PubMed ID: 29229473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ion Channel Modulators in Cystic Fibrosis.
    Gentzsch M; Mall MA
    Chest; 2018 Aug; 154(2):383-393. PubMed ID: 29750923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. At the forefront of cystic fibrosis Basic Science research: 16th ECFS Basic Science Conference.
    Taggart CC; Weldon S; Mall MA
    J Cyst Fibros; 2020 Mar; 19(2):169-170. PubMed ID: 32063486
    [No Abstract]   [Full Text] [Related]  

  • 6. Letter to the editor: Challenges and opportunities in the development of future CFTR modulator options for people with CF.
    Downey DG; Taylor-Cousar J
    J Cyst Fibros; 2020 Jan; 19(1):e1-e2. PubMed ID: 31672556
    [No Abstract]   [Full Text] [Related]  

  • 7. CFTR functional measurements in human models for diagnosis, prognosis and personalized therapy: Report on the pre-conference meeting to the 11th ECFS Basic Science Conference, Malta, 26-29 March 2014.
    Beekman JM; Sermet-Gaudelus I; de Boeck K; Gonska T; Derichs N; Mall MA; Mehta A; Martin U; Drumm M; Amaral MD
    J Cyst Fibros; 2014 Jul; 13(4):363-72. PubMed ID: 24882694
    [No Abstract]   [Full Text] [Related]  

  • 8. The influence of CFTR complex alleles on precision therapy of cystic fibrosis.
    Chevalier B; Hinzpeter A
    J Cyst Fibros; 2020 Mar; 19 Suppl 1():S15-S18. PubMed ID: 31883651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.
    Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP
    Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fundamental and translational research in Cystic Fibrosis - why we still need it.
    Farinha CM; Brodsky JL; Pedemonte N
    J Cyst Fibros; 2023 Mar; 22 Suppl 1():S1-S4. PubMed ID: 36577595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the basic mechanisms in Cystic Fibrosis: Promoting data presentation and discussion at the 16th ECFS Basic Science Conference.
    Callebaut I; Mense M; Farinha CM
    J Cyst Fibros; 2020 Mar; 19 Suppl 1():S1-S4. PubMed ID: 31932104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systems Approaches to Unravel Molecular Function: High-content siRNA Screen Identifies TMEM16A Traffic Regulators as Potential Drug Targets for Cystic Fibrosis.
    Pinto MC; Botelho HM; Silva IAL; Railean V; Neumann B; Pepperkok R; Schreiber R; Kunzelmann K; Amaral MD
    J Mol Biol; 2022 Mar; 434(5):167436. PubMed ID: 34990652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.
    McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW
    Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma membrane-localized TMEM16 proteins are indispensable for expression of CFTR.
    Benedetto R; Ousingsawat J; Cabrita I; Pinto M; Lérias JR; Wanitchakool P; Schreiber R; Kunzelmann K
    J Mol Med (Berl); 2019 May; 97(5):711-722. PubMed ID: 30915480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chloride channels and cystic fibrosis of the pancreas.
    Gray MA; Winpenny JP; Verdon B; McAlroy H; Argent BE
    Biosci Rep; 1995 Dec; 15(6):531-41. PubMed ID: 9156582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy.
    Lommatzsch ST; Taylor-Cousar JL
    Ther Adv Respir Dis; 2019; 13():1753466619844424. PubMed ID: 31027466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cystic Fibrosis Papers of the Year 2016.
    Doull I
    Paediatr Respir Rev; 2018 Mar; 26():10-12. PubMed ID: 28539217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural mechanisms for defective CFTR gating caused by the Q1412X mutation, a severe Class VI pathogenic mutation in cystic fibrosis.
    Yeh JT; Yu YC; Hwang TC
    J Physiol; 2019 Jan; 597(2):543-560. PubMed ID: 30408177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs during pregnancy and breast feeding in women diagnosed with Cystic Fibrosis - An update.
    Kroon MAGM; Akkerman-Nijland AM; Rottier BL; Koppelman GH; Akkerman OW; Touw DJ
    J Cyst Fibros; 2018 Jan; 17(1):17-25. PubMed ID: 29233472
    [No Abstract]   [Full Text] [Related]  

  • 20. Two Small Molecules Restore Stability to a Subpopulation of the Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant Disease-causing Mutation.
    Meng X; Wang Y; Wang X; Wrennall JA; Rimington TL; Li H; Cai Z; Ford RC; Sheppard DN
    J Biol Chem; 2017 Mar; 292(9):3706-3719. PubMed ID: 28087700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.